v3.25.2
Reportable Segment Information (Tables)
 9 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Summary of Financial Information for Each Reportable Segment

The following table presents various financial information for each reportable segment:

 

Three months ended

 

 

Nine months ended

 

 

June 30

 

 

June 30

 

(In millions - unaudited)

2025

 

 

2024

 

 

2025

 

 

2024

 

SALES

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

162

 

 

$

195

 

 

$

468

 

 

$

617

 

Personal Care

 

147

 

 

 

175

 

 

 

426

 

 

 

473

 

Specialty Additives

 

131

 

 

 

150

 

 

 

380

 

 

 

429

 

Intermediates

 

33

 

 

 

36

 

 

 

104

 

 

 

108

 

Intersegment sales(a)

 

(10

)

 

 

(12

)

 

 

(31

)

 

 

(36

)

$

463

 

 

$

544

 

 

$

1,347

 

 

$

1,591

 

OPERATING INCOME (LOSS)

 

 

 

 

 

 

 

 

 

 

 

Life Sciences(b)

$

(343

)

 

$

43

 

 

$

(301

)

 

$

125

 

Personal Care

 

25

 

 

 

31

 

 

 

64

 

 

 

59

 

Specialty Additives(c)

 

(345

)

 

 

10

 

 

 

(343

)

 

 

(40

)

Intermediates

 

4

 

 

 

6

 

 

 

6

 

 

 

22

 

Unallocated and other(d)

 

(49

)

 

 

(151

)

 

 

(262

)

 

 

(223

)

 

$

(708

)

 

$

(61

)

 

$

(836

)

 

$

(57

)

DEPRECIATION EXPENSE

 

 

 

 

 

 

 

 

 

 

 

Life Sciences(e)

$

17

 

 

$

9

 

 

$

48

 

 

$

29

 

Personal Care(f)

 

7

 

 

 

10

 

 

 

23

 

 

 

27

 

Specialty Additives(g)

 

34

 

 

 

20

 

 

 

60

 

 

 

97

 

Intermediates

 

3

 

 

 

3

 

 

 

9

 

 

 

9

 

 

$

61

 

 

$

42

 

 

$

140

 

 

$

162

 

AMORTIZATION EXPENSE

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

5

 

 

$

6

 

 

$

13

 

 

$

18

 

Personal Care

 

8

 

 

 

10

 

 

 

26

 

 

 

32

 

Specialty Additives

 

2

 

 

 

3

 

 

 

7

 

 

 

8

 

Intermediates

 

—

 

 

 

—

 

 

 

1

 

 

 

1

 

 

$

15

 

 

$

19

 

 

$

47

 

 

$

59

 

EBITDA(h)

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

(321

)

 

$

58

 

 

$

(240

)

 

$

172

 

Personal Care

 

40

 

 

 

51

 

 

 

113

 

 

 

118

 

Specialty Additives

 

(309

)

 

 

33

 

 

 

(276

)

 

 

65

 

Intermediates

 

7

 

 

 

9

 

 

 

16

 

 

 

32

 

Unallocated and other

 

(49

)

 

 

(151

)

 

 

(262

)

 

 

(223

)

 

$

(632

)

 

$

—

 

 

$

(649

)

 

$

164

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

June 30

 

 

September 30

 

(In millions - unaudited)

2025

 

 

2024

 

TOTAL ASSETS

 

 

 

 

 

Life Sciences

$

1,531

 

 

$

1,778

 

Personal Care

 

699

 

 

 

950

 

Specialty Additives

 

1,048

 

 

 

1,516

 

Intermediates

 

118

 

 

 

127

 

Unallocated and other

 

1,225

 

 

 

1,274

 

 

$

4,621

 

 

$

5,645

 

 

 

 

 

 

 
(a)
Intersegment sales from Intermediates are accounted for at prices that approximate fair value. All other intersegment sales are accounted for at cost.
(b)
Includes goodwill impairment of $375 million for Life Sciences for the three and nine months ended June 30, 2025.
(c)
Includes goodwill impairment of $331 million for Specialty Additives for the three and nine months ended June 30, 2025.
(d)
Includes a $8 million gain on sale and a $183 million impairment charge related to the sale of the Avoca business for the nine months ended June 30, 2025, and a $99 million impairment charge related to the sale of the Nutraceuticals business for the three and nine months ended June 30, 2024, within the loss on acquisitions and divestitures, net caption of the Statements of Condensed Consolidated Income (Loss).
(e)
Depreciation includes accelerated depreciation of $8 million and $21 million for Life Sciences for the three and nine months ended June 30, 2025, respectively.
(f)
Depreciation includes accelerated depreciation of $1 million for Personal Care for both the three and nine months ended June 30, 2024.
(g)
Depreciation includes accelerated depreciation of $19 million for Specialty Additives for both the three and nine months ended June 30, 2025, and $7 million and $55 million for the three and nine months ended June 30, 2024, respectively.
(h)
Excludes loss from discontinued operations, net of income taxes and other net periodic benefit loss. See the Statements of Condensed Consolidated Comprehensive Income (Loss) for applicable amounts excluded.